RBC8 is primarily used in research settings as a selective inhibitor of the enzyme cyclin-dependent kinase 8 (CDK8). It plays a key role in studying signaling pathways related to gene transcription, particularly the Wnt/β-catenin and STAT pathways, which are involved in cancer development. Due to its ability to modulate transcriptional regulation, RBC8 is investigated for its potential in oncology, especially in leukemia and colorectal cancer models. It helps scientists understand how CDK8 inhibition affects tumor growth and cell proliferation, making it a valuable tool compound in drug discovery and molecular pharmacology.